🎥 Start here: trusted cancer info
New videos weekly—subscribe below ⬇️
https://youtu.be/vcetk3Ixiv0?si=70_ooCr-9ytO2G6y
Take a look—you might be surprised by who doesn’t need testing, and who definitely should.
youtu.be/ctQZ8Fd7AAE?...
Take a look—you might be surprised by who doesn’t need testing, and who definitely should.
youtu.be/ctQZ8Fd7AAE?...
Each week, I share short, evidence-based videos on YouTube—breaking down the latest in treatment trends, side effect relief, and survivorship care.
youtu.be/vcetk3Ixiv0
#cancer #bcsm @ascopost.bsky.social @ascocancer.bsky.social
Each week, I share short, evidence-based videos on YouTube—breaking down the latest in treatment trends, side effect relief, and survivorship care.
youtu.be/vcetk3Ixiv0
#cancer #bcsm @ascopost.bsky.social @ascocancer.bsky.social
#bcsm @ascocancer.bsky.social
#bcsm @ascocancer.bsky.social
If #camizestrant is approved based on #SERENA-6, it would mark the first therapy triggered by a rising #ESR1 mutation before visible recurrence.
That means #ctDNA won’t just monitor—it could guide treatment.
@ascocancer.bsky.social
#bcsm
If #camizestrant is approved based on #SERENA-6, it would mark the first therapy triggered by a rising #ESR1 mutation before visible recurrence.
That means #ctDNA won’t just monitor—it could guide treatment.
@ascocancer.bsky.social
#bcsm
VERITAC-2 tests a next-gen PROTAC therapy targeting ESR1 mutations.
Breakthrough science at #ASCO25 🎯
@ascocancer.bsky.social @ascopost.bsky.social @erikahamilton9.bsky.social
VERITAC-2 tests a next-gen PROTAC therapy targeting ESR1 mutations.
Breakthrough science at #ASCO25 🎯
@ascocancer.bsky.social @ascopost.bsky.social @erikahamilton9.bsky.social
#sabcs24 was a throwback to those old days of following posts, seeing different perspectives on data, and seeing colleagues in San Antonio.
#hcsm has a new home. #oncsm #oncsky